Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

NCT00743795 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

252

Enrollment

INDUSTRY

Sponsor class

Conditions

HCV Infection

Interventions

DRUG: placebo
DRUG: GS-9190
DRUG: Peginterferon Alfa 2a
DRUG: Ribavirin

Sponsor

Gilead Sciences